BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37359351)

  • 1. Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells.
    Duan J; Zhang Z; Du J; Zhang J; Li M; Li C
    Onco Targets Ther; 2023; 16():425-440. PubMed ID: 37359351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K inhibitor 3-MA promotes the antiproliferative activity of esomeprazole in gastric cancer cells by downregulating EGFR via the PI3K/FOXO3a pathway.
    Du J; Xu Q; Zhao H; Jia X; Ba N; Peng F; Zhang Z
    Biomed Pharmacother; 2022 Apr; 148():112665. PubMed ID: 35228068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
    Yang H; Li H; Lu S; Shan S; Guo Y
    Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low concentration of chloroquine enhanced efficacy of cisplatin in the treatment of human ovarian cancer dependent on autophagy.
    Zhu J; Zheng Y; Zhang H; Zhu J; Sun H
    Am J Transl Res; 2017; 9(9):4046-4058. PubMed ID: 28979680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
    Yin S; Mai Z; Liu C; Xu L; Xia C
    Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
    Ma J; Liu L; Ling Y; Zheng J
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.
    Chen Y; Wang L; Zhou J
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIFC3 Promotes Proliferation, Migration, and Invasion in Colorectal Cancer
    Liao H; Zhang L; Lu S; Li W; Dong W
    Front Genet; 2022; 13():848926. PubMed ID: 35812733
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardamonin inhibits the progression of oesophageal cancer by inhibiting the PI3K/AKT signalling pathway.
    Wang Z; Liu H; Hu Q; Shi L; Lü M; Deng M; Luo G
    J Cancer; 2021; 12(12):3597-3610. PubMed ID: 33995637
    [No Abstract]   [Full Text] [Related]  

  • 13. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway.
    Shen Z; Xue D; Wang K; Zhang F; Shi J; Jia B; Yang D; Zhang Q; Zhang S; Jiang H; Luo D; Li X; Zhong Q; Zhang J; Peng Z; Han Y; Sima C; He X; Hao L
    BMC Urol; 2022 May; 22(1):79. PubMed ID: 35610639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway.
    Liao XZ; Tao LT; Liu JH; Gu YY; Xie J; Chen Y; Lin MG; Liu TL; Wang DM; Guo HY; Mo SL
    Cancer Cell Int; 2017; 17():124. PubMed ID: 29299027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
    Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian cancer cells via targeting P13K pathway.
    Muhanmode Y; Wen MK; Maitinuri A; Shen G
    Hum Exp Toxicol; 2022; 41():9603271221095929. PubMed ID: 35722665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
    Ma N; Zhao Y
    Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alantolactone Inhibits Melanoma Cell Culture Viability and Migration and Promotes Apoptosis by Inhibiting Wnt/β-Catenin Signaling.
    Zhang L; Chen J; Chen Y; Zou D; Pu Y; Wei M; Huang Y; Li Y; Huang Q; Chen J
    Anticancer Agents Med Chem; 2023; 23(1):94-104. PubMed ID: 35598249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.